A leadless intracardiac transcatheter pacing system

Dwight Reynolds, G. Duray, Razali Omar, Kyoko Soejima, Petr Neuzil, Shu Zhang, Calambur Narasimhan, Clemens Steinwender, Josep Brugada, Michael Lloyd, Paul R. Roberts, Venkata Sagi, John Hummel, Maria Grazia Bongiorni, Reinoud E. Knops, Christopher R. Ellis, Charles C. Gornick, Matthew A. Bernabei, Verla Laager, Kurt StrombergEric R. Williams, J. Harrison Hudnall, Philippe Ritter

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

BACKGROUND: A leadless intracardiac transcatheter pacing system has been designed to avoid the need for a pacemaker pocket and transvenous lead. METHODS In a prospective multicenter study without controls, a transcatheter pacemaker was implanted in patients who had guideline-based indications for ventricular pacing. The analysis of the primary end points began when 300 patients reached 6 months of follow-up. The primary safety end point was freedom from system-related or procedure-related major complications. The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (≤2.0 V at a pulse width of 0.24 msec and an increase of ≤1.5 V from the time of implantation). The safety and efficacy end points were evaluated against performance goals (based on historical data) of 83% and 80%, respectively. We also performed a post hoc analysis in which the rates of major complications were compared with those in a control cohort of 2667 patients with transvenous pacemakers from six previously published studies. RESULTS The device was successfully implanted in 719 of 725 patients (99.2%). The Kaplan-Meier estimate of the rate of the primary safety end point was 96.0% (95% confidence interval [CI], 93.9 to 97.3; P

Original languageEnglish
Pages (from-to)533-541
Number of pages9
JournalNew England Journal of Medicine
Volume374
Issue number6
DOIs
Publication statusPublished - Feb 11 2016

Fingerprint

Safety
Kaplan-Meier Estimate
Multicenter Studies
Prospective Studies
Guidelines
Confidence Intervals
Equipment and Supplies
Lead

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reynolds, D., Duray, G., Omar, R., Soejima, K., Neuzil, P., Zhang, S., ... Ritter, P. (2016). A leadless intracardiac transcatheter pacing system. New England Journal of Medicine, 374(6), 533-541. https://doi.org/10.1056/NEJMoa1511643

A leadless intracardiac transcatheter pacing system. / Reynolds, Dwight; Duray, G.; Omar, Razali; Soejima, Kyoko; Neuzil, Petr; Zhang, Shu; Narasimhan, Calambur; Steinwender, Clemens; Brugada, Josep; Lloyd, Michael; Roberts, Paul R.; Sagi, Venkata; Hummel, John; Bongiorni, Maria Grazia; Knops, Reinoud E.; Ellis, Christopher R.; Gornick, Charles C.; Bernabei, Matthew A.; Laager, Verla; Stromberg, Kurt; Williams, Eric R.; Hudnall, J. Harrison; Ritter, Philippe.

In: New England Journal of Medicine, Vol. 374, No. 6, 11.02.2016, p. 533-541.

Research output: Contribution to journalArticle

Reynolds, D, Duray, G, Omar, R, Soejima, K, Neuzil, P, Zhang, S, Narasimhan, C, Steinwender, C, Brugada, J, Lloyd, M, Roberts, PR, Sagi, V, Hummel, J, Bongiorni, MG, Knops, RE, Ellis, CR, Gornick, CC, Bernabei, MA, Laager, V, Stromberg, K, Williams, ER, Hudnall, JH & Ritter, P 2016, 'A leadless intracardiac transcatheter pacing system', New England Journal of Medicine, vol. 374, no. 6, pp. 533-541. https://doi.org/10.1056/NEJMoa1511643
Reynolds D, Duray G, Omar R, Soejima K, Neuzil P, Zhang S et al. A leadless intracardiac transcatheter pacing system. New England Journal of Medicine. 2016 Feb 11;374(6):533-541. https://doi.org/10.1056/NEJMoa1511643
Reynolds, Dwight ; Duray, G. ; Omar, Razali ; Soejima, Kyoko ; Neuzil, Petr ; Zhang, Shu ; Narasimhan, Calambur ; Steinwender, Clemens ; Brugada, Josep ; Lloyd, Michael ; Roberts, Paul R. ; Sagi, Venkata ; Hummel, John ; Bongiorni, Maria Grazia ; Knops, Reinoud E. ; Ellis, Christopher R. ; Gornick, Charles C. ; Bernabei, Matthew A. ; Laager, Verla ; Stromberg, Kurt ; Williams, Eric R. ; Hudnall, J. Harrison ; Ritter, Philippe. / A leadless intracardiac transcatheter pacing system. In: New England Journal of Medicine. 2016 ; Vol. 374, No. 6. pp. 533-541.
@article{a2f6487900d04f64985291cac76c5d37,
title = "A leadless intracardiac transcatheter pacing system",
abstract = "BACKGROUND: A leadless intracardiac transcatheter pacing system has been designed to avoid the need for a pacemaker pocket and transvenous lead. METHODS In a prospective multicenter study without controls, a transcatheter pacemaker was implanted in patients who had guideline-based indications for ventricular pacing. The analysis of the primary end points began when 300 patients reached 6 months of follow-up. The primary safety end point was freedom from system-related or procedure-related major complications. The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (≤2.0 V at a pulse width of 0.24 msec and an increase of ≤1.5 V from the time of implantation). The safety and efficacy end points were evaluated against performance goals (based on historical data) of 83{\%} and 80{\%}, respectively. We also performed a post hoc analysis in which the rates of major complications were compared with those in a control cohort of 2667 patients with transvenous pacemakers from six previously published studies. RESULTS The device was successfully implanted in 719 of 725 patients (99.2{\%}). The Kaplan-Meier estimate of the rate of the primary safety end point was 96.0{\%} (95{\%} confidence interval [CI], 93.9 to 97.3; P",
author = "Dwight Reynolds and G. Duray and Razali Omar and Kyoko Soejima and Petr Neuzil and Shu Zhang and Calambur Narasimhan and Clemens Steinwender and Josep Brugada and Michael Lloyd and Roberts, {Paul R.} and Venkata Sagi and John Hummel and Bongiorni, {Maria Grazia} and Knops, {Reinoud E.} and Ellis, {Christopher R.} and Gornick, {Charles C.} and Bernabei, {Matthew A.} and Verla Laager and Kurt Stromberg and Williams, {Eric R.} and Hudnall, {J. Harrison} and Philippe Ritter",
year = "2016",
month = "2",
day = "11",
doi = "10.1056/NEJMoa1511643",
language = "English",
volume = "374",
pages = "533--541",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - A leadless intracardiac transcatheter pacing system

AU - Reynolds, Dwight

AU - Duray, G.

AU - Omar, Razali

AU - Soejima, Kyoko

AU - Neuzil, Petr

AU - Zhang, Shu

AU - Narasimhan, Calambur

AU - Steinwender, Clemens

AU - Brugada, Josep

AU - Lloyd, Michael

AU - Roberts, Paul R.

AU - Sagi, Venkata

AU - Hummel, John

AU - Bongiorni, Maria Grazia

AU - Knops, Reinoud E.

AU - Ellis, Christopher R.

AU - Gornick, Charles C.

AU - Bernabei, Matthew A.

AU - Laager, Verla

AU - Stromberg, Kurt

AU - Williams, Eric R.

AU - Hudnall, J. Harrison

AU - Ritter, Philippe

PY - 2016/2/11

Y1 - 2016/2/11

N2 - BACKGROUND: A leadless intracardiac transcatheter pacing system has been designed to avoid the need for a pacemaker pocket and transvenous lead. METHODS In a prospective multicenter study without controls, a transcatheter pacemaker was implanted in patients who had guideline-based indications for ventricular pacing. The analysis of the primary end points began when 300 patients reached 6 months of follow-up. The primary safety end point was freedom from system-related or procedure-related major complications. The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (≤2.0 V at a pulse width of 0.24 msec and an increase of ≤1.5 V from the time of implantation). The safety and efficacy end points were evaluated against performance goals (based on historical data) of 83% and 80%, respectively. We also performed a post hoc analysis in which the rates of major complications were compared with those in a control cohort of 2667 patients with transvenous pacemakers from six previously published studies. RESULTS The device was successfully implanted in 719 of 725 patients (99.2%). The Kaplan-Meier estimate of the rate of the primary safety end point was 96.0% (95% confidence interval [CI], 93.9 to 97.3; P

AB - BACKGROUND: A leadless intracardiac transcatheter pacing system has been designed to avoid the need for a pacemaker pocket and transvenous lead. METHODS In a prospective multicenter study without controls, a transcatheter pacemaker was implanted in patients who had guideline-based indications for ventricular pacing. The analysis of the primary end points began when 300 patients reached 6 months of follow-up. The primary safety end point was freedom from system-related or procedure-related major complications. The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (≤2.0 V at a pulse width of 0.24 msec and an increase of ≤1.5 V from the time of implantation). The safety and efficacy end points were evaluated against performance goals (based on historical data) of 83% and 80%, respectively. We also performed a post hoc analysis in which the rates of major complications were compared with those in a control cohort of 2667 patients with transvenous pacemakers from six previously published studies. RESULTS The device was successfully implanted in 719 of 725 patients (99.2%). The Kaplan-Meier estimate of the rate of the primary safety end point was 96.0% (95% confidence interval [CI], 93.9 to 97.3; P

UR - http://www.scopus.com/inward/record.url?scp=84959276537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959276537&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1511643

DO - 10.1056/NEJMoa1511643

M3 - Article

C2 - 26551877

AN - SCOPUS:84959276537

VL - 374

SP - 533

EP - 541

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -